The tweet was deleted by the author.
But we saved everything 🙂.
Niagen Bioscience, recognized for its leadership in NAD+ precursor technology, appears on the cover of Business by LA Times Studios for April 2026.
The company reports over 40 published studies, 300 global research collaborations, and more than 500 industry partnerships supporting its patented NAD+ offerings. Available in oral, injectable, and topical formats, Niagen Bioscience’s consumer business is cash-flow-positive, underscoring its strong market position. The announcement reflects continued momentum in both scientific credibility and commercial performance.
Niagen Bioscience previously received validation from top health experts, including Andrew Huberman and Rhonda Patrick, who confirmed their use of Tru Niagen. The company also earned a published USP ingredient monograph for Nicotinamide Riboside Chloride in dietary supplements, affirming its quality standards, according to a prior report. These milestones follow its expanding global presence and ongoing product development.